Moreover, certain treatments, particularly TPO‐RAs, have been associated with an expected increased risk of thrombosis, which raises questions about how best to manage thrombotic risk in patients with ITP [11, 12]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.